Research Solutions

Research Solutions did $49M in annual revenue and the whole company is worth about $76M.

If you own RSSS, you own a tiny research software company finally showing real profit.

rsss

technology · software small cap updated mar 20, 2026
$2.35
market cap ~$76M · 52-week range $2–$4
xvary composite: 54 / 100 · below average
our overall rating — combines growth, value, risk, and momentum
Start here if you're new
what it is
It sells software that helps researchers find, access, and manage scientific papers without drowning in paywalls and bad search results.
how it gets paid
Last year Research Solutions made $49M in revenue. Article Galaxy transactions was the main engine at $19.6M, or 40% of sales.
why it's growing
Revenue grew 9.9% last year. Revenue rose 104% vs. prior year in the latest quarter from EDGAR-supplied data.
what just happened
Research Solutions posted $24M in quarterly revenue and $0.04 EPS, showing the profit story is finally showing up in reported numbers.
At a glance
B balance sheet — gets the job done, barely
50/100 earnings predictability — expect surprises
19.6x trailing p/e — priced about right
9.1% return on capital — nothing to write home about
$0.04 fy2025 eps est
xvary composite: 54/100 — below average
What they do
It sells software that helps researchers find, access, and manage scientific papers without drowning in paywalls and bad search results.
This business sits inside your research workflow. Once your team loads subscriptions, article rights, and internal libraries into Article Galaxy, leaving is painful. The company has 136 employees supporting a $49M revenue base, and that scale matters because a 51.5% gross margin means each extra software dollar drops through better than document-by-document selling.
software microcap saas research-tools ai-search
How they make money
$49M annual revenue · their business grew +9.9% last year
Article Galaxy transactions
$19.6M
5.0%
Article Galaxy subscriptions
$12.3M
+8.0%
Discover platform
$9.8M
+18.0%
Resolute.ai and scite.ai tools
$4.9M
+25.0%
Related services and other
$2.4M
+3.0%
The products that matter
research workflow software
Platform
$26.9M · 55% of revenue
This segment generated $26.9M last year and grew 12%. It is where the better economics live, and it sits on top of access to 160+ million publication pages.
12% growth
one-off document delivery
Transactions
$22.1M · 45% of revenue
This $22.1M segment still matters because it is nearly half the business, but it declined about 2%. That makes it funding source and headwind at the same time.
shrinking
Key numbers
$49M
annual revenue
This is the current size of the business. Against a roughly $76M market cap, you are paying about 1.6 times sales for a profitable software company.
51.5%
gross margin
Gross margin → money left after delivering the product → so what: RSSS keeps about $0.52 of every revenue dollar before overhead.
7.2%
operating margin
Operating margin → profit after running the business → so what: the company is profitable, but the cushion is still thin.
9.1%
return on capital
Return on capital → profit earned on money invested in the business → so what: decent, not elite, and still below software stars.
Financial health
B
strength
  • balance sheet grade B — adequate — nothing special
  • risk rank 3 — safer than 50% of stocks
  • price stability 45 / 100
B — functional but not a standout on the balance sheet.
Total return vs. market

Return history isn't available for RSSS right now.

source: institutional data · return history unavailable
What just happened
beat estimates
Research Solutions posted $24M in quarterly revenue and $0.04 EPS, showing the profit story is finally showing up in reported numbers.
Revenue rose 104% vs. prior year in the latest quarter from EDGAR-supplied data. Gross margin was 51.5%, and that mix shift matters more than the headline growth because still sees just $0.04 of FY2025 EPS.
$24M
revenue
$0.04
eps
51.5%
gross margin
the number that mattered
The key number was 51.5% gross margin because margin improvement is what turns a $49M niche software business into an actually investable one.
source: company earnings report, 2026

Get this snapshot in your inbox

This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.

weekly updates earnings alerts plain english no spam
What could go wrong

The top risk is the transaction business declining faster than the platform grows.

med
mix shift stalls
Transactions still represent $22.1M, or 45% of revenue, and declined about 2%. If that side keeps fading while Platform stays near 12% growth, total company growth can look fine one quarter and flat the next.
The entire bull case depends on the 55% software side growing fast enough to outrun the 45% services side shrinking.
med
profit base is still thin
Quarterly net income was $547k. That is real profit, but it is not a cushion. A modest miss in revenue or a reversal in gross margin can erase a lot of earnings quickly.
At this scale, small operating changes have oversized effects on EPS and sentiment.
med
good gross margin does not automatically mean good moat
Gross margin reached 52.4%, but operating margin sits at 7.2% and return on capital is 9.1%. That gap says the business has better product economics than overall corporate economics.
If operating leverage never shows up, the stock stays a small niche software name instead of getting treated like a real compounder.
If 45% of revenue keeps shrinking while the 55% platform side grows only 12%, the math leaves little room for error on a $49.0M revenue base.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
platform growth staying above 12%
This is the cleanest test of the thesis. If Platform slips into single digits, the transition story starts looking like stasis in a software wrapper.
calendar
Q3 FY2026 earnings
Expected May 7, 2026. Analysts expect EPS of $0.04 on $13.01M revenue. The real question is whether margin gains hold while revenue re-accelerates.
trend
transaction decline rate
A 2% slide is manageable. A faster drop changes the whole revenue mix and forces Platform to do much more of the lifting.
risk
whether new institutional deals repeat
The University of Pretoria rollout is useful because it is specific. One win is a case study. A second and third win would start looking like a sales engine.
Analyst rankings
earnings predictability
50 / 100
In human-speak, analysts do not see this as a clean, steady earnings story. Expect more noise than you get from larger software names.
risk rank
3
This sits around the middle of the pack on risk. Not a balance-sheet disaster, not a safe-haven stock either.
balance sheet grade
B
B means functional. The company has cash and no debt, but the grade does not rescue the investment case if growth disappoints.
source: institutional data
Institutional activity

institutional ownership data for RSSS is being compiled.

source: institutional data
Price targets
3-5 year target range
n/a n/a
$2 current price
n/a target midpoint · n/a from current
target data not available

Want the deeper analysis?

The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.

see plans from $5/mo
The deep dive
RSSS
xvary deep dive
rsss
the full analysis is in the works.
what you'll get
dcf valuation model
bull / base / bear scenarios
competitive moat breakdown
quarterly earnings tracker
operating model projections
risk matrix with kill criteria
original price target + conviction
updated with every earnings
free · no spam · you'll be first to read it